Pelage Pharmaceuticals
Pelage Pharmaceuticals has announced topline results from its Phase 2a trial of PP405, a new topical aimed at reactivating dormant hair follicle stem cells to treat androgenic alopecia (AGA). While the data show promise for a regenerative approach, there are important limitations and open questions to keep in mind. The Study The Phase 2a study…
The Aesthetic Tech Forum 2024 is underway (January 25th and 26th) and features a session titled “Revitalizing Radiance: Advances in Hair Restoration“. Panelists include: Wajdie Ahmad, Executive Chairman & COO of Amplifica Holdings Group, Inc.; Amplifica is a biopharmaceutical company with several treatments in the pipeline targeted towards androgenic alopecia (AMP-303, AMP-203, and AMP-601). Drew…
The UCLA spinout with a focus on hair follicle stem cells has fully emerged into the public eye. Pelage Pharma PP405 More than six years in the making, Pelage Pharmaceuticals has an official website and an exciting drug candidate on its hands – PP405. Back in 2017, Drs. Bill Lowry and Heather Christofk of the…
Back in August 2017, UCLA researchers made headlines by discovering a new way to activate hair follicle stem cells. This was done through a metabolite called lactate. William Lowry and Heather Christofk of UCLA’s Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research were responsible for the lactate discovery. Lowry and Christofk…